WO2002089829A3 - Polymorphism in the eosinophil cationic protein (ecp) used in the treatment of e.g. cancer - Google Patents

Polymorphism in the eosinophil cationic protein (ecp) used in the treatment of e.g. cancer Download PDF

Info

Publication number
WO2002089829A3
WO2002089829A3 PCT/IB2002/002555 IB0202555W WO02089829A3 WO 2002089829 A3 WO2002089829 A3 WO 2002089829A3 IB 0202555 W IB0202555 W IB 0202555W WO 02089829 A3 WO02089829 A3 WO 02089829A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
polymorphism
ecp
treatment
eosinophil cationic
Prior art date
Application number
PCT/IB2002/002555
Other languages
French (fr)
Other versions
WO2002089829A2 (en
Inventor
Per Venge
Original Assignee
Innoventus Project Ab
Per Venge
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innoventus Project Ab, Per Venge filed Critical Innoventus Project Ab
Priority to AU2002311573A priority Critical patent/AU2002311573A1/en
Publication of WO2002089829A2 publication Critical patent/WO2002089829A2/en
Publication of WO2002089829A3 publication Critical patent/WO2002089829A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/27—Endoribonucleases producing 3'-phosphomonoesters (3.1.27)
    • C12Y301/27001—Ribonuclease T2 (3.1.27.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention relates to novel eosinophil cationic proteins characterized by the presence of a single nucleotide polymorphism. The presence of such polymorphism has been correlated to an advantageous phenotype being a reduced disposition to cancer or cancer-related disorders.
PCT/IB2002/002555 2001-05-08 2002-05-08 Polymorphism in the eosinophil cationic protein (ecp) used in the treatment of e.g. cancer WO2002089829A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002311573A AU2002311573A1 (en) 2001-05-08 2002-05-08 Polymorphism in the eosinophil cationic protein (ecp) used in the treatment of e.g. cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0111194.7 2001-05-08
GB0111194A GB0111194D0 (en) 2001-05-08 2001-05-08 Sequences

Publications (2)

Publication Number Publication Date
WO2002089829A2 WO2002089829A2 (en) 2002-11-14
WO2002089829A3 true WO2002089829A3 (en) 2003-05-30

Family

ID=9914200

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/002555 WO2002089829A2 (en) 2001-05-08 2002-05-08 Polymorphism in the eosinophil cationic protein (ecp) used in the treatment of e.g. cancer

Country Status (3)

Country Link
AU (1) AU2002311573A1 (en)
GB (1) GB0111194D0 (en)
WO (1) WO2002089829A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005085851A2 (en) * 2004-03-03 2005-09-15 Adra Chaker N Granulocyte subtype-selective receptors and ion channels and uses thereof
CN113373218A (en) * 2021-08-04 2021-09-10 杭州浙大迪迅生物基因工程有限公司 Primer group and kit for detecting mRNA expression of human eosinophil cationic protein

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085766A2 (en) * 2000-05-09 2001-11-15 Innoventus Project Ab Novel eosinophil cationic proteins used in the treatment of asthmatic and allergic disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085766A2 (en) * 2000-05-09 2001-11-15 Innoventus Project Ab Novel eosinophil cationic proteins used in the treatment of asthmatic and allergic disorders

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
DATABASE EM-HUM [online] 10 August 1990 (1990-08-10), XP002902817, retrieved from EBI Database accession no. HSECP1 *
DATABASE GENBANK [online] XP002902813, Database accession no. AX304714 *
DATABASE GENBANK [online] XP002902814, Database accession no. AX304713 *
DATABASE GENBANK [online] XP002902815, Database accession no. AX304716 *
DATABASE GENBANK [online] XP002902816, Database accession no. AX304715 *
DATABASE MEDLINE [online] August 1990 (1990-08-01), HAMANN K J ET AL: "Structure and chromosome localization of the human eosinophil-derived neurotoxin and eosinophil cationic protein genes: evidence for intronless coding sequences in the ribonuclease gene superfamily.", XP002227824, Database accession no. NLM2387583 *
GENOMICS. UNITED STATES AUG 1990, vol. 7, no. 4, August 1990 (1990-08-01), pages 535 - 546, ISSN: 0888-7543 *
MOLIN D ET AL: "The serum levels of eosinophil cationic protein (ECP) are related to the infiltration of eosinophils in the tumours of patients with Hodgkin's disease.", LEUKEMIA & LYMPHOMA. SWITZERLAND JUL 2001, vol. 42, no. 3, July 2001 (2001-07-01), pages 457 - 465, XP002227823, ISSN: 1042-8194 *
ROSENBERG HELENE F ET AL: "Characterization of the eosinophil granule proteins recognized by the activation-specific antibody EG2.", JOURNAL OF LEUKOCYTE BIOLOGY, vol. 56, no. 4, 1994, pages 502 - 506, XP002227821, ISSN: 0741-5400 *
TRULSON A ET AL: "The eosinophil granule proteins in serum, but not the oxidative metabolism of the blood eosinophils, are increased in cancer.", BRITISH JOURNAL OF HAEMATOLOGY, vol. 98, no. 2, 1997, pages 312 - 314, XP002227820, ISSN: 0007-1048 *
VENGE PER ET AL: "Molecules in focus eosinophil cationic protein (ECP).", INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, vol. 30, no. 4, April 1998 (1998-04-01), pages 433 - 437, XP002227822, ISSN: 1357-2725 *
VON WASIELEWSKI R ET AL: "Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin's disease, allowing for known prognostic factors.", BLOOD, vol. 95, no. 4, 15 February 2000 (2000-02-15), pages 1207 - 1213, XP002227819, ISSN: 0006-4971 *
ZHANG JIANZHI ET AL: "Sequence variation at two eosinophil-associated ribonuclease loci in humans.", GENETICS, vol. 156, no. 4, December 2000 (2000-12-01), pages 1949 - 1958, XP002227818, ISSN: 0016-6731 *

Also Published As

Publication number Publication date
WO2002089829A2 (en) 2002-11-14
GB0111194D0 (en) 2001-06-27
AU2002311573A1 (en) 2002-11-18

Similar Documents

Publication Publication Date Title
WO2003016475A3 (en) Nucleic acid and amino acid sequences involved in pain
WO2003029262A3 (en) The human mob-5 (il-24) receptors and uses thereof
WO2004074455A3 (en) Fc REGION VARIANTS
MXPA03008573A (en) Process for the polymerization of olefins.
AU2002365811A1 (en) Methods for the selection and cloning of nucleic acid molecules free of unwanted nucleotide sequence alterations
WO2004028454A3 (en) 1, 3, 5-triazines for treatment of viral diseases
WO2003018758A3 (en) Reagents and methods for smooth muscle therapies
WO1999053040A3 (en) Human nucleic acid sequences from ovarian tumour tissue
ZA200404418B (en) Gene which codes for novel proteins
MXPA02006997A (en) Process for the preparation of peptides.
WO2002089829A3 (en) Polymorphism in the eosinophil cationic protein (ecp) used in the treatment of e.g. cancer
MXPA03010728A (en) B7 related protein-2 molecules and uses thereof.
PL374550A1 (en) Il-17 like molecules and uses thereof
WO2003012070A3 (en) Gene associated with bone disorders
WO2001040521A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
EP1437405A4 (en) Gene overexpression system
AU2002330401A1 (en) Gene overexpression system
WO2004050834A3 (en) GPC99 AND GPC99a: METHODS AND COMPOSITIONS FOR TREATING CANCER
WO2001085766A3 (en) Novel eosinophil cationic proteins used in the treatment of asthmatic and allergic disorders
AU2002343043A1 (en) Processing nucleic acid
AU2001282084A1 (en) Nucleotide sequences which code for the sigh gene
WO2003018629A8 (en) Cage antigen
IL152062A0 (en) G protein coupled receptor
WO2005060667A3 (en) Nucleic acid and amino acid sequences involved in pain
WO2002036780A8 (en) Stearoyl-coa desaturase gene promoter

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP